Preoperative Systemic Immune-Inflammation Index is a Potential Biomarker in Adult Patients with High-Grade Gliomas Undergoing Radical Resection
Yu-Ting Jiang,Tian-Cheng Wang,Wei Zhang
DOI: https://doi.org/10.2147/jir.s423488
IF: 4.5
2023-08-17
Journal of Inflammation Research
Abstract:Yu-Ting Jiang, 1 Tian-Cheng Wang, 2, &ast Wei Zhang 1, &ast 1 Department of Radiology, Brain Hospital of Hunan Province, the School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, People's Republic of China; 2 Department of Radiology, the Second Xiangya Hospital of Central South University, Changsha, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tian-Cheng Wang; Wei Zhang, Email ; Background: Increasing evidence has highlighted that systemic immune-inflammation index (SII), a recently developed prognostic biomarker that utilizes peripheral platelet, lymphocyte and neutrophil counts, is associated with unfavorable prognosis in various tumors. Nevertheless, the prognostic significance of SII in high-grade gliomas patients undergoing radical resection remains unclear. Therefore, the present study aimed to assess the potential of SII as a prognostic biomarker in this patient population. Methods: A total of 111 adult patients with high-grade gliomas who underwent radical resection were consecutively enrolled in this investigation. The study involved the categorization of patients into high and low SII groups using predetermined cut-off values. Subsequently, forward stepwise logistic regression was employed to identify autonomous predictors for early gliomas recurrence. To mitigate the impact of confounding factors, a propensity score matching (PSM) analysis was performed between high and low SII patients. Finally, the Kaplan-Meier approach was utilized to compare the progression-free survival (PFS) and overall survival (OS) of the two groups. Results: The study involved the categorization of patients into two groups based on their SII levels, namely high SII (> 604.8) and low SII (≤ 604.8) groups. Forward stepwise logistic regression revealed that high SII (p < 0.001) and tumor size ≥ 50 mm (p < 0.001) were significantly related to early recurrence of gliomas. Furthermore, the results indicate that PFS and OS were significantly shorter in the high SII group compared to the low SII group, both before and after PSM (p < 0.05). Conclusion: Preoperative biomarker SII can serve as a prognostic biomarker for early recurrence and prognosis in patients with high-grade gliomas undergoing radical resection. Furthermore, the combination of tumor size and SII demonstrates a robust predictive capacity for early recurrence and prognosis in this patient population. Keywords: systemic immune-inflammation index, high-grade gliomas, resection, survival, prognosis Gliomas represent the most prevalent malignancies of the central nervous system (CNS), comprising over 50% of CNS malignancies in adults. 1,2 Traditionally, gliomas are classified into two primary types based on histological characterization: low-grade gliomas (I–II) and high-grade (III–IV) gliomas. 3,4 The high-grade gliomas pose significant challenges in treatment and have a poor prognosis due to their high recurrence rate, despite initial maximal radical resection. 5,6 One of the main challenges is that gliomas exhibit invasive growth, and the determination of the tumor boundary through conventional radiology is typically challenging. 7 Consequently, the extent of tumor resection is frequently confined to the boundary identified by preoperative radiological assessment, rather than the precise histopathological boundary and this limitation may contribute significantly to the propensity for gliomas recurrence following radical resection. Overall, patients with high-grade gliomas who undergo radical resection exhibit varying outcomes with 5-year survival rate fluctuates between 5.5% and 75.2%, which can be attributed to the differences in tumor burdens, histopathological status, and immune response status. 8–10 Consequently, to enhance risk stratification and improve prognostic accuracy, effective prognostic biomarkers are required for this population of high-grade gliomas patients who undergo radical resection. In the context of cancer progression, the hallmarks of inflammatory response and immunoregulation are widely recognized as crucial factors that contribute to processes such as priming, proliferation, angiogenesis, and migration. 11,12 It is reported that high-grade gliomas lead to a inflammatory and immunosuppressive environment both locally and systemically, which presents significant challenges that can negatively impact clinical outcomes and the effectiveness of therapeutic interventions. 13,14 For example, elevated levels of myeloid-derived suppressor cells have been found in the tumor microenvironment of gliomas while higher proporti -Abstract Truncated-
immunology